AnBogen Therapeutics, a Taiwan-based, clinical-stage biotechnology company focused on precision oncology, announced on Monday that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

According to the company, the data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer (CRC) and reveal a novel mechanism for overcoming chemotherapy resistance in pancreatic cancer.

Preclinical data confirms that Imofinostat, acting as an HDAC inhibitor, effectively modulates the tumour microenvironment. By synergising with immune checkpoint inhibitors and anti-angiogenic agents, it converts 'cold tumours' into 'hot tumours,' significantly enhancing the immune system's ability to recognise and eliminate cancer cells. AnBogen says that this provides a robust scientific foundation for its ongoing global clinical trials.

Additionally, for highly challenging KRAS-mutant pancreatic cancer, the study reveals that Imofinostat precisely regulates the HDAC3-NRF2 signalling pathway -- a key driver of chemo-resistance. By intervening in this pathway, Imofinostat significantly boosts tumour sensitivity to chemotherapy, offering a promising new therapeutic strategy for patients with this aggressive malignancy.

AnBogen will present these breakthroughs during the session 'PO.ET09.01 - Epigenetic Modulators 1' on Tuesday, April 21, 2026, from 9:00 AM to 12:00 PM in San Diego.